BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Akari Therapeutics PLC (“Akari” or the “Company”) (NASDAQ: AKTX) concerning the Company and its officers’ potential violation of federal securities laws.
On May 11, 2017, the Company announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Akari Board of Directors reviews whether Dr. Roshwalb had any involvement with a research report that contained material inaccuracies. On this news the Company’s shares were halted, and fell in after-market trading on May 11, 2017.
If you purchased Akari securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.